{"abstract": "The chief executive of Sanofi-Aventis reiterated his belief that French company\u2019s $18.5 billion hostile bid for Genzyme represented good value for the U.S. biotechnology firm, saying: \u201cNothing in what Genzyme has said in recent weeks would cause us to change our offer.\u201d", "web_url": "https://dealbook.nytimes.com/2010/10/28/sanofi-aventis-defends-genzyme-bid/", "snippet": "The chief executive of Sanofi-Aventis reiterated his belief that French company\u2019s $18.5 billion hostile bid for Genzyme represented good value for the U.S. biotechnology firm, saying: \u201cNothing in what Genzyme has said in recent weeks would cause u...", "lead_paragraph": "Sanofi-Aventis, after reporting strong third-quarter earnings on Thursday, reiterated that it believed its $18.5 billion hostile takeover bid for the American biotechnology firm Genzyme represented good value.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Sanofi Posts Strong Profit and Defends Genzyme Bid", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Genzyme Corp", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Sanofi-Aventis SA", "rank": 2, "major": "N"}], "pub_date": "2010-10-28T11:38:15+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/c865f708-83b7-50e3-9c91-fe3cf6d2168c", "word_count": 193, "uri": "nyt://article/c865f708-83b7-50e3-9c91-fe3cf6d2168c"}